Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: A high-activity, dose-dense weekly regimen for advanced breast cancer (Q61900317)

From Wikidata

Jump to navigation Jump to search

scientific article published in August 1999

Language	Label	Description	Also known as
English	Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: A high-activity, dose-dense weekly regimen for advanced breast cancer	scientific article published in August 1999

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10509155%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10509155%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Diana Giannarelli

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10509155%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

author name string

C Nisticò

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10509155%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

C Garufi

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10509155%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

S Barni

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10509155%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

L Frontini

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10509155%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

D A Gallà

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10509155%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

A Vaccaro

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10509155%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

A M D'Ottavio

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10509155%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

E Terzoli

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10509155%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

publication date

1 August 1999

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10509155%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10509155%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10509155%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10509155%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

937-942

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10509155%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Chemotherapy of breast cancer: current views and results.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008324329562

7 January 2021

based on heuristic

inferred from DOI database lookup

Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008324329562

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008324329562

7 January 2021

based on heuristic

inferred from DOI database lookup

Epirubicin treatment of advanced breast carcinoma with the weekly low-dose regimen

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008324329562

7 January 2021

based on heuristic

inferred from DOI database lookup

A weekly schedule of epirubicin in pretreated advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008324329562

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008324329562

7 January 2021

based on heuristic

inferred from DOI database lookup

Vinorelbine as first-line chemotherapy for metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008324329562

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008324329562

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008324329562

7 January 2021

based on heuristic

inferred from DOI database lookup

Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008324329562

7 January 2021

based on heuristic

inferred from DOI database lookup

Vinorelbine: An active, non cross-resistant drug in advanced breast cancer. Results from a phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008324329562

7 January 2021

based on heuristic

inferred from DOI database lookup

Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008324329562

7 January 2021

based on heuristic

inferred from DOI database lookup

Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008324329562

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008324329562

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008324329562

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008324329562

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008324329562

7 January 2021

based on heuristic

inferred from DOI database lookup

Vinorelbine and epirubicin in metastatic breast cancer. A dose finding study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008324329562

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-response effect of adjuvant chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008324329562

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008324329562

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1008324329562

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10509155%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10509155%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q61900317&oldid=1448059765"